Results 201 to 210 of about 9,397,444 (297)
Neighborhood Socioeconomic Status and Short‐Term Functional Outcomes in Systemic Lupus Erythematosus
Objective Individuals with systemic lupus erythematosus (SLE) can accumulate functional status (FS) impairment. We evaluated the association between neighborhood socioeconomic disadvantage, as measured by the Area Deprivation Index (ADI), and FS in a national SLE sample.
Baljeet Rai +7 more
wiley +1 more source
Report of the FDA's expert panel on hormone therapy. [PDF]
Pinkerton JV +5 more
europepmc +1 more source
Objective We characterized emergency department (ED) gout visits and identified patient characteristics and health services patterns contributing to ED presentations. Methods We conducted a population‐based study of ED gout visits in Ontario, Canada, between 2014 and 2023.
Timothy S. H. Kwok +7 more
wiley +1 more source
Distinct media requirements for dopaminergic neuron reprogramming from human glia and fibroblasts. [PDF]
Laurin K +4 more
europepmc +1 more source
Objective The objective of this article is to identify perceptions of patients with systemic lupus erythematosus (SLE) regarding artificial intelligence (AI)–based online symptom assessment tools, and the potential of these tools to address diagnostic barriers.
Olivia A. Stein +7 more
wiley +1 more source
A note on a generalized single step theory for any number of hierarchical genomic matrices. [PDF]
Pérez-Enciso M.
europepmc +1 more source
Objective Although the definition of a gout flare is well established, the state of gout flare resolution has not yet been defined. This study aimed to explore patients’ experiences and perceptions of gout flare resolution. Methods Semistructured interviews were conducted with 24 people with gout, guided by open‐ended questions exploring their ...
Sarah Stewart +5 more
wiley +1 more source
Emerging PFAS: Current Concerns, Remediation, and Future Perspectives. [PDF]
Mashima R.
europepmc +1 more source
Dual antihypertensive fixed-dose combinations approved for first-line use on the Pharmaceutical Benefits Scheme. [PDF]
europepmc +1 more source

